Navtemadlin Shows Biomarker Response in Patients with R/R Myelofibrosis
Key claim: Navtemadlin shows biomarker responses in relapsed/refractory myelofibrosis and is being tested in the Phase 3 POIESIS trial as add-on therapy to ruxolitinib in JAK inhibitor-naïve patients with suboptimal Jakafi response.
Abstract
Phase 3 POIESIS study exploring navtemadlin in combination with ruxolitinib for JAK inhibitor-naïve myelofibrosis; patients showing suboptimal response to Jakafi alone are randomly assigned to receive navtemadlin or placebo as add-on therapy.
Why this matters
Navtemadlin targets the MDM2–p53 axis, a non-JAK mechanism, and its advancement into Phase 3 POIESIS as a ruxolitinib add-on in suboptimal responders broadens the MF combination landscape beyond BET, XPO1, BCL-2, and anemia-targeted partners. The ‘suboptimal ruxolitinib response’ enrollment criterion also carves out a clinically meaningful middle population between frontline-naïve and overt JAKi-refractory disease, where disease-modifying add-ons are most needed. Biomarker responses in R/R MF support a plausible mechanistic rationale underpinning the late-phase bet.